Hello,
Novel modalities pose unique considerations for the risk assessment and bioanalysis of immunogenicity. The goal of this working group is to provide a forum to discuss challenges and to share experiences. Modalities of interest include, but are not limited to:
- Cellular therapies
- Gene therapies
- Liposomal delivery systems
- Oligonucleotide
- Complex biologics
The group will tentatively meet on the second to last Monday of the month from 1 pm to 2pm. Interested members should contact Michael Swanson ([email protected]) or Kun Yang ([email protected]) with a preferred day of the week/time along with modalities of interest.
Best,
Michael and Kun
------------------------------
Michael Swanson
Associate Scientific Director
Janssen
Spring House PA
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------